Ipek Erdogan-Trinkaus

CIK: 0002047026

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ETON

Eton Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

ETON
Eton Pharmaceuticals, Inc.
Jul 31, 2026
Award(A)
Common Stock
Direct
80K shares-
ETON
Eton Pharmaceuticals, Inc.
Jan 12, 2026
Award(A)
Employee Stock Option (Right to Buy)
Direct
40.7K shares-
ETON
Eton Pharmaceuticals, Inc.
Jan 12, 2026
Award(A)
Restricted Stock Units
Direct
25.9K shares-
ETON
Eton Pharmaceuticals, Inc.
Dec 12, 2025
Tax Payment(F)
Direct
85 shares at avg. $16.90$1K

		Type	Shares	Price		Ownership
Jul 31, 2026	ETON Eton Pharmaceuticals, Inc.	Award(A) Common Stock	80,000	-	-	Direct
Jan 12, 2026	ETON Eton Pharmaceuticals, Inc.	Award(A) Employee Stock Option (Right to Buy)	40,655	-	-	Direct
Jan 12, 2026	ETON Eton Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	25,856	-	-	Direct
Dec 12, 2025	ETON Eton Pharmaceuticals, Inc.	Tax Payment(F)	85	$16.90	$1,436	Direct

1-4 of 4 transactions

About Erdogan-Trinkaus Ipek

Erdogan-Trinkaus Ipek (SEC CIK 0002047026) files insider reports with the SEC as Chief Commercial Officer of Eton Pharmaceuticals, Inc. (ETON).

Signal8 holds 4 ownership filings by Erdogan-Trinkaus Ipek (1 Form 3, 3 Form 4), filed between Dec 9, 2024 and Aug 4, 2026. Those filings report 4 transactions, from Dec 12, 2025 to Jul 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Erdogan-Trinkaus Ipek's filings is in DEERPARK, IL.

Recent filings by Erdogan-Trinkaus Ipek

Jul 31, 2026: Grant or award of ETON derivative securities (Form 4, code A).
Jan 12, 2026: Grants or awards of ETON derivative securities (2 lines, Form 4, code A).
Dec 12, 2025: Tax withholding of ETON shares (Form 4, code F).

Other insiders filing for Eton Pharmaceuticals, Inc. (ETON)

Krempa David, Chief Business Officer
MAIER PAUL V, Director
BRYNJELSEN SEAN, President & CEO
Radosavljevic Danka, Chief Operating Officer
CASAMENTO CHARLES J, Director
Matthews Judith M., Chief Financial Officer

How to read Form 4 transaction codes